China rejected US trade overtures Thursday, demanding all tariffs be lifted and denying any progress in talks. "The US should ...

Germany's Merck KGaA is nearing a roughly $3.5 billion deal for SpringWorks Therapeutics , the Wall Street Journal reported ...

Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Merck (MRK) stock trades flat as Halozyme Therapeutics (HALO) files patent infringement suit linked to MRK's new injectable ...

Germany's Merck KGaA is nearing a deal for SpringWorks Therapeutics, a source close to the deal said on Thursday. Shares of ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

Merck lowered its full-year profit guidance and said tariffs would mean an extra $200 million in costs this year. The stock ...

Tariff worries continue hanging over companies as they report their latest financial results and try to provide guidance on ...